DiaMedica Therapeutics Inc
Research DiaMedica Therapeutics Inc (DMAC) on Bullrun: market cap USD 363.17M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDMAC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 363.17M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 35.10M
- Free cash flow-USD 31.03M
Valuation Snapshot
latest market cap is USD 363.17M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 32.77M | -USD 29.10M | n/a | -1.23 | USD 15.65M | USD 240.00K | USD 56.11M |
| FY2024 | USD 0 | -USD 24.44M | -USD 22.10M | n/a | -1.02 | USD 3.03M | USD 340.00K | USD 40.72M |
| FY2023 | n/a | -USD 19.38M | -USD 18.75M | n/a | -1.08 | USD 4.54M | USD 400.00K | USD 51.06M |
| FY2022 | n/a | -USD 13.68M | -USD 11.59M | n/a | n/a | USD 4.73M | USD 25.00K | USD 31.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 363.17M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 427.79M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 232.51M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 107.79M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 41.78M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 98.63M | n/a | n/a | n/a |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is DiaMedica Therapeutics Inc's market cap?
DiaMedica Therapeutics Inc's market capitalization is USD 363.17M.
What does DiaMedica Therapeutics Inc do?
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.